MAR 07, 2016 04:57 AM PST

Tracing The Path Of Alzheimer's

The problem with many neurodegenerative diseases is that they are difficult to diagnose and observe when the patient is still living. Alzheimer’s, CTE and other forms of dementia are diagnosed by eliminating other causes, rather than being seen directly. However, new research led by scientists at UC Berkeley shows that PET scans can discover and even track the stages of Alzheimer’s disease in adults who do not yet show cognitive decline. The research also yielded important information about the two key proteins thought to be responsible for the disease, tau and beta-amyloid.
Brain scans showing amyloid and tau deposits
Positron emission tomography or PET scans provided the data for the study which was published March 2nd in the journal Neuron.  While small, the results were still significant. The make up of the participants was as follows: A total of 53 adults participated. Five were aged 20-26 and 33 were aged 64-90. Both of these groups were cognitively health. The other 15 were aged 53-77 and had been diagnosed with probable Alzheimer’s dementia.  
 
PET scans can show the build-up of the protein tau in the brain. A staging process developed in 1991 by German scientist Heiko Braak is the standard by which Alzheimer’s disease can be quantified, but until now, it’s only been possible post-mortem.
 
In a press release from UC Berkeley’s School of Public Health, Dr. William Jagust, the study principal investigator and a professor at the Hellen Wills Neuroscience Institute said,  “Braak staging was developed through data obtained from autopsies, but our study is the first to show the staging in people who are not only alive, but who have no signs of cognitive impairment. This opens the door to the use of PET scans as a diagnostic and staging tool.” The Braak staging has six levels, based on the amount of accumulation of tau protein in the brain. The fact that Jagust and his team were able to stage their results according to the Braak scale using PET scans is a first in neuroscience. 
 
The study also provided new information on the interaction of tau as well as beta-amyloid plaques. The conventional wisdom has been that these amyloid deposits were the main cause of Alzheimer’s but more recent research has shown that tau deposits are also a likely factor since it gets tangled in the structure of neurons and impairs the synaptic connections, leading to memory loss and cognitive decline.
 
The team addressed the issue of these two proteins and how they might related since many people have tau or amyloid present in their brain, but some will go on to develop Alzheimer’s and some will not.  Jagust stated, “Amyloid may somehow facilitate the spread of tau, or tau may initiate the deposition of amyloid. We don’t know. We can’t answer that at this point. All I can say is that when amyloid starts to show up, we start to see tau in other parts of the brain, and that is when real problems begin. We think that may be the beginning of symptomatic Alzheimer’s disease.”
 
Funding from the National Institutes of Health helped support this research. Jagust worked with study co-lead authors Michael Schöll, a visiting scholar, and Samuel Lockhart, a postdoctoral fellow, both at UC Berkeley’s Helen Wills Neuroscience Institute. Check out the video below to see more about the study and what their findings could mean.
 
 
About the Author
  • I'm a writer living in the Boston area. My interests include cancer research, cardiology and neuroscience. I want to be part of using the Internet and social media to educate professionals and patients in a collaborative environment.
You May Also Like
AUG 21, 2019
Cell & Molecular Biology
AUG 21, 2019
Some Activity Restored in a Pig Brain Hours After Death
Challenging medical assumptions about brain function after death, researchers restored activity in cells and circulation in a pig brain four hours after death....
AUG 21, 2019
Drug Discovery
AUG 21, 2019
How Exactly Does General Anesthesia Work?
General anesthesia is a medical miracle that enabled millions of patients to have life-saving surgeries without pain. However, despite the miraculous work ...
AUG 21, 2019
Drug Discovery
AUG 21, 2019
Promising Hypertension Drug for Alzheimer Disease
In a study led by the American Heart Association, the blood pressure drug nilvadipine (a calcium channel blocker) was found to increase blood flow to the b...
AUG 21, 2019
Genetics & Genomics
AUG 21, 2019
Are Our Instincts Really Genetic?
Genetic explanations for our instincts are incomplete. Although they explain to some degree how we learn and suggest how these learnings are passed on, the...
AUG 21, 2019
Genetics & Genomics
AUG 21, 2019
Same Repetitive DNA Sequence at the Root of Several Rare Neurodegenerative Disorders
Reporting in Nature Genetics, scientists have now identified a genetic feature underlying three neurodegenerative diseases....
AUG 21, 2019
Drug Discovery
AUG 21, 2019
Drug Targets Early Instigators of Alzheimer Disease
The two solidifying instigators of Alzheimer -disease (AD)—amyloid beta and the tau protein—have long been the topic of study for AD researcher...
Loading Comments...